Akin Akinc was scouring his email spam box last summer, looking for a missing message, when he stumbled across an unexpected email from a quite recognizable name: Feng Zhang.
Zhang, one of the leading scientists in the groundbreaking field of genetic editing, had reached out two days prior to discuss a new company he was working on. Since helping to discover CRISPR-Cas9 — often referred to as molecular scissors that can cut into the genome and edit DNA — Zhang has founded at least six companies, worth around $4.6 billion combined.
Zhang was approaching Akinc, the then-head of oncology at Alnylam, about his seventh business: Aera Therapeutics, which launched Thursday with $193 million from ARCH Venture Partners, GV, and Lux Capital. The deal was first reported by Insider.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.